Running Title: Interaction of oral cyclosporin A/amphotericin B Abbreviations: CyA, cyclosporin A; AMB; amphotericin B; BA, bioavailability; CYP, cytochrome P450; P-gp, P-glycoprotein; DEX, dexamethasone; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GTP, γ-glutamyltranspeptidase; BUN, blood urea nitrogen; AUC 0-24h , area under the blood concentration-time curve from 0 to 24 h; MRT, mean residence time; CL tot , total clearance; Vd ss , distribution volume at the steady-state -1-ABSTRACT: The trough level of blood concentration of cyclosporin A (CyA) in a patients receiving immunotherapy was observed to decrease following coadministration of amphotericin B (AMB). We confirmed this clinical observation in experiments using Wistar rats intravenously given AMB (1.5 or 3.0 mg/kg) or saline (control) for 4 days, followed by CyA (10 mg/kg). The blood concentration of CyA after iv or po administration in both AMB groups was significantly decreased compared with the control. The oral bioavailability of CyA after 1.5 or 3.0 mg/kg AMB treatment was decreased to 67 or 46%, respectively, of that of the control group. AMB treatment increased the expression levels of mdr1a and mdr1b mRNAs in duodenum to about 3 times the control, and expression of CYP3A2 mRNA in liver was increased to about twice the control. The induction of their mRNAs by AMB treatment increased the level of P-gp and CYP3A2 protein to about twice the control. These findings suggest that the oral bioavailability of CyA is reduced as a result of both increased efflux transport via P-glycoprotein in the duodenum and an increased firstpass effect of CYP3A2-mediated hepatic metabolic activity, induced by AMB. We suggest that careful monitoring of CyA levels is necessary in the event of AMB administration to patients receiving immunotherapy with CyA.
Introduction
There have been many reports of drug interactions involving cyclosporin A (CyA), and clinically, we have encountered a patient receiving immunotherapy with CyA in whom the blood concentration of CyA was decreased upon coadministration of amphotericin B (AMB) (Fig. 1) .
It is well known that CyA is a substrate of both the efflux transporter Pglycoprotein (P-gp) and the metabolic enzyme cytochrome P450 (CYP3A) [1] [2] [3] . P-gp and/or CYP3A limit the oral bioavailability of digoxin [4] , rifampin [4] , vinblastine [5] , dextromethorphan [6] and CyA [7, 8] . We have already shown that the blood concentration of CyA is reduced by pretreatment with dexamethasone [9] , cyclophosphamide [10] or levothyroxine [11] in rats, owing to induction of P-gp and CYP3A2 in liver and intestine. In those reports, we demonstrated that the oral bioavailability of CyA is primarily controlled by the level of CYP3A in the upper small intestine under physiological conditions, whereas after treatment with inducers, P-gp in the upper intestine also plays a significant role as an absorption barrier to CyA. Thus, we speculated that the reason for the decrease of blood concentration of CyA in the patient mentioned above might have been induction of P-gp and CYP. However, no report is currently available on drug interaction between CyA and AMB.
Therefore, in this study, we examined the mechanism of the decrease of blood concentration of CyA by using rats treated with AMB.
Materials and methods

Chemicals -3-
The measurement range of blood concentration was 25-1500 ng/mL. The cross-reactivities with the metabolites of CyA were 19.4% for M1 and less than 5% for other metabolites.
Determination of laboratory data
Blood samples were collected from the jugular vein under light ether anesthesia at 24 h after the last treatment with AMB, and the plasma was separated by centrifugation and stored at -30°C. The measurements of laboratory data were entrusted to SRL Co. Ltd. (Tokyo, Japan).
Reverse Transcriptase-polymerase Chain Reaction (RT-PCR) Assay
Total RNA was isolated from the liver and intestine by using an Isogen Kit Taq DNA polymerase (Gibco-BRL). Reported primers were used for rat mdr1a (511 bp) [13] , for rat mdr1b (451 bp) [13] , for rat CYP3A2 (252 bp) [14] , and for rat ß-actin (456 bp) [15] . Each cycle consisted of 30 sec at -5-94°C, 60 sec at 62°C, and 75 sec at 72°C for mdr1a, mdr1b, and CYP3A2, and 30 sec at 94°C, 60 sec at 58°C, and 75 sec at 72°C for ß-actin. The PCR reaction was run for 26 cycles for liver, for 34 cycles for intestine and for 22 cycles for ß-actin.
Preparation of Microsomes and Plasma Membrane Fraction
For preparation of microsomes, the liver was homogenized in three volumes of 100 mM Tris-HCl buffer (100 mM KCl, 1 mM EDTA, pH 7.4).
Microsomes were prepared as reported previously [16] and stored at -80°C until use. The intestine was quickly removed and washed with buffer containing 2 mM HEPES, 0.9% NaCl and 0.5 mM phenylmethylsulfonyl fluoride (PMSF). Mucosa was scraped off with a slide glass on ice and homogenized in a buffer containing 300 mM mannitol, 5 mM EDTA, 5 mM HEPES and 1 mM PMSF (pH 7.1). The homogenate was centrifuged at 10,000 g for 20 min, and the supernatant was centrifuged at 105,000 g for 60 min at 4°C. The pellet was added to the buffer containing 500 mM KCl, 1 mM EDTA, 2 mM DTT and 50 mM KPB (pH 7.4) and again centrifuged at 105,000 g for 60 min at 4°C. The pellet was added to the buffer containing 1 mM EDTA, 2 mM DTT and 50 mM KPB (pH 7.4), then stored at -80°C until use.
For the preparation of plasma membrane, the liver was homogenized in 10 mM Tris-HCl buffer (pH 7.5) containing 2 mM CaCl 2 at 4°C. The homogenate was centrifuged at 3,500 g for 10 min, and the supernatant was then centrifuged at 15,000 g for 30 min. The pellet was washed, resuspended in 50 mM Tris-HCl buffer (pH 7.2), and twice centrifuged at 10,000 g for 5 min, then stored at -80°C until use. The intestine was quickly removed and washed with ice-cold isotonic saline containing 1 mM phenylmethylsulfonyl fluoride (PMSF). Mucosa was scraped off -6-with a slide glass on ice and homogenized in a buffer containing 250 mM sucrose, 50 mM Tris-HCl (pH 7.4), and 1 mM PMSF. The homogenate was centrifuged at 3,000 g for 10 min, and the supernatant was again centrifuged at 15,000 g for 30 min. The pellet was resuspended in 0.5 mL of a buffer containing 50 mM mannitol, 50 mM Tris-HCl (pH 7.4), and 1 mM PMSF, and stored at -80°C until use. Protein contents were measured according to the method of Lowry et al. [17] .
SDS-PAGE and Immunoblotting
SDS-PAGE and immunoblotting with peroxidase/antiperoxidase staining of the plasma membrane for P-gp and of the microsomes for CYP3A were carried out essentially as described by Laemmli [18] and Guengerich et al. [19] . The amounts of sample protein of liver and intestine were 4 and 200 μg for CYP3A or 30 and 300 µg for P-gp, respectively. The sample protein was electrophoresed on 10% sodium dodecyl sulfatepolyacrylamide gel and transferred onto PVDF membrane filters (Millipore Co., Billerica, MA). After having been blocked with 5% skim milk, the filters were incubated overnight at 4°C with primary antibody, mouse anti-P-gp C219 (Dako Co., Carpinteria, CA) and rabbit anti-rat CYP3A2 antibody (Daiichi Pure Chemicals Co. Ltd., Tokyo, Japan), and for 1 h with secondary antibody, anti-mouse IgG HRP-linked antibody (Cell Signaling, Beverly, MA) and mouse anti-rabbit IgG-HRP (Santa Cruz Bio., Santa Cruz, CA). Thereafter, the sample was extensively washed with phosphate-buffered saline. The immunopositive band was detected by means of a light-emitting nonradioactive detection system (Amersham International plc, Little Chalfont, Buckinghamshire, UK) with Kodak XOmat R film (Eastman Kodak Co., Rochester, NY).
Data Analysis
The pharmacokinetic parameters were estimated according to modelindependent moment analysis as described by Yamaoka et al. [20] . The data were analyzed using Student's t test to compare the unpaired mean values of two sets of data. The number of determinations is noted in each table and figure. A value of P< 0.05 or 0.01 was taken to indicate a significant difference between sets of data. The electrophoresis results were analyzed by using NIH Image software.
Case report
The patient was a 23-year-old man (56 kg) who had received bone marrow transplantation for acute myelogenous leukaemia 2 months before. He These results suggest that the initial AMB treatment caused slight renal impairment. Laboratory data in rats after AMB treatment Table 2 shows the laboratory data for rats treated or not treated with AMB 
Experimental results
Pharmacokinetics of CyA in rats with AMB treatment
RT-PCR Analysis of mdr1a, mdr1b and CYP3A2 mRNAs in intestine and liver
Figures 4 shows the effect of AMB treatment (1.5 or 3.0 mg/kg/day, i.v., for 4 days) on the expression of mdr1a, mdr1b and CYP3A2 mRNAs in the duodenum, ileum and liver at 24 h after the last treatment. The expression levels of mdr1a and mdr1b mRNAs were significantly increased in the duodenum, but little changed in the ileum and liver by the AMB treatment. On the other hand, the expression of CYP3A2 was significantly induced, in the liver only, by both AMB treatments. Figure 5 shows the effect of the AMB treatment (3.0 mg/kg/day, i.v., for 4 days) on the expression levels of P-gp and CYP3A proteins which were confirmed by Western blot analysis. The protein levels of P-gp in the duodenum was elevated to about twice the untreated control level by AMB treatment, but the level in the ileum and liver were hardly changed by AMB. On the other hand, the protein levels of CYP3A in the liver was elevated to about twice the control level by AMB treatment, while the level in the duodenum and liver showed little change.
Expression of P-gp and CYP3A in intestine and liver
Discussion
In order to understand why the blood concentration of CyA in a patient receiving immunotherapy decreased following coadministration of AMB, we examined the effect of repeated i.v. administration of AMB (1.5 or 3.0 mg/kg) for 4 days on the disposition kinetics of CyA in rats after i.v.
or p.o. administration (Figs. 2, 3) . We designed that AMB is administered with 1.5 or 3.0 mg/kg to rats because total clearance of AMB of rats is about 5-times higher than that of human (0.5 mg/kg) [21] . As we previously clarified that dexamethasone [9] and cyclophosphamide [10] within 4 days after the co-administration induce P-gp and CYP3A2, in this study the AMB co-administerd intravenously to rats for 4 days. (Table 1) .
It is well known that renal failure is the main side effect of AMB in clinical practice. There are some reports indicating that the disposition kinetics of CyA is influenced by renal failure in rats. Shibata et al. [22] reported that CYP3A and P-gp in liver and intestine are not likely to be involved in lowering the oral bioavailability of CyA in gentamicin-induced acute renal failure, and that a change in bile function is responsible for the marked decrease. Huang et al. [23] reported that the expression level of P-gp in rats with glycerol-induced acute renal failure was increased 2.5-fold in the kidney, but not in the liver or brain. Leblond et al. [24] reported that chronic renal failure is associated with a decrease in total liver CYP450 (mainly CYP2C11, CYP3A1 and CYP3A2) activity in rats, and -12-this leads to a significant decrease in drug metabolism. In the rats, hepatic function was not impaired, as judged from the laboratory data, whereas increases in the values of serum creatinine and BUN indicated an appreciable impairment of renal function by the high-AMB treatment (Table 2) . However, the increases of serum creatinine and BUN were not large compared with the increases of about 3-to 5-fold and 2-to 5-fold in model rats with gentamicin-or glycerol-induced renal failure, respectively [22] [23] [24] . Therefore, we considered that the AMB-induced renal impairment was not great even in the high-AMB group, and may have had only a slight influence on the excretion of CyA, which is metabolized mainly by CYP3A.
We found that in our model the expression of mdr1a and mdr1b mRNAs was characteristically induced about 3-fold in the duodenum compared with the control, but was only slightly increased in the ileum and liver by both AMB treatments (Fig. 4) . Also, the expression of CYP3A2
mRNA was increased about 2-fold over the control in the liver. These results are broadly consistent with our previous findings in mice treated with dexamethasone (DEX) [25, 26] . Unlike DEX, AMB did not induce a substantial increase of CYP3A2 mRNA expression in intestine, possibly because the dose levels of AMB were relatively low. This would be consistent with the relatively minor renal impairment. The studies with DEX [9] [10] [11] 26] indicated that increased mRNA levels of mdr1a, mdr1b
and CYP3A2 mRNAs are well reflected in increased levels of P-gp and CYP3A2 proteins. In this study, also the induction of their mRNAs by AMB treatment increased the level of P-gp and CYP3A2 proteins (Fig. 5) .
Therefore, we consider that the oral bioavailability of CyA was reduced in our present animal model as a result of increased efflux transport via Pglycoprotein in the duodenum and an increased first-pass effect of hepatic CYP3A2 induced by AMB. But, it was not observed that there is a great -13-difference in the t 1/2 values of CyA among three groups. Therefore, we thought that the induce of CYP3A2 in the liver influences slightly to the disposition kinetics of CyA. Previously we suggested that, under physiological conditions, the oral bioavailability of CyA is mainly controlled by CYP3A in the upper intestine, rather than liver, but when Pgp is induced by steroid, the intestinal absorption of CyA may be inhibited [26] . Therefore, we consider that the decrease of BA by AMB treatment is cause by the intestinal absorption decrease via induced P-gp.
In the case of our patient, the stable trough values of blood CyA concentration during repeated p.o. administration of CyA were decreased after repeated intravenous infusion administration of AMB was started, and the decrease continued for 3 weeks. During this period, the laboratory data indicated relatively minor impairment of hepatic and renal function by AMB. Further, the patient has been received in combination with hydrocortisone after the start of the transplantation, however, it was not observed that the hydrocortisone treatment influences slightly on the plasma level of CyA because the low dose of hydrocortisone (50-100 mg/day). Therefore, we think that the clinical observations can also be explained mainly in terms of the induction of P-gp in intestine by the AMB treatment.
We previously clarified that the induction of P-gp and CYP3A2
continues for 2 weeks after the final DEX treatment [27] . Here, the patient received repeated administration of AMB for 40 days, so it was difficult to predict when the levels of P-gp and CYP3A2 expression would recover to the control level; therefore, we chose to increase the dose of CyA gradually. The level of blood CyA concentration began to increase 7 days after increasing the dose of CyA from 120 mg/day to 160 mg/day, and after the dose of CyA was further increased to 240 mg/day, the blood CyA concentration reached 210 ng/mL. Therefore, the blood CyA -14-concentration might have recovered to about 100 ng/mL within 40 days after the start of AMB treatment, if the dose had been kept at 120 mg/day throughout. In other words, the P-gp and CYP3A activities might return to the control levels within several weeks after the start of the AMB treatment in spite of repeating the AMB treatment, leading to normalization of CyA bioavailability. Further, there are species differences in hepatic metabolism and susceptibility to metabolic changes, so that further evaluations need to be done in vitro study using human hepatic microsome and/or human hepatocytes.
In Table 1 . Pharmacokinetic parameters of CyA with or without AMB (1.5 or 3.0 mg/kg) in rats Rats were intravenously or orally administered with CyA (10 mg/kg) at 24 h after the last AMB treatment in untreated rats and rats treated with AMB at 1.5 or 3.0 mg/kg for 4 days. Pharmacokinetic parameters were estimated according to model-independent moment analysis. Each value represents the mean ± SD of four mice. a) area under blood concentration-time curve from 0 to 24 h, b) mean residence time from 0 to 24 h, c) blood total clearance, d) distribution volume at the steady-state, e) elimination half-life * , **Significant difference between the control group and both AMB groups at P < 0.05 and 0.01, respectively. 
